The specter of generic rivalry has long loomed above copyright’s iconic drug, Sildenafil, sparking questions about the outlook of similar medicinal portfolios. While initial times saw significant gains, the exclusivity end has created the door for cheaper substitutes, possibly reducing profitability and presenting a significant hazard for shareho